XML 39 R30.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) - Research services combined with an IP license € in Thousands, $ in Thousands | 6 Months Ended |  |
--- | --- | --- | ---
Jun. 30, 2022 EUR (€) | Jun. 30, 2021 EUR (€) | Jun. 30, 2022 USD ($) | Dec. 31, 2021 EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |
Upfront and milestones payments included in contract liabilities | € 120,278 |  |  | € 142,095
Revenue recognized from upfront and milestones payments | 31,818 | € 27,731 |  |
CRISPR |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |
Upfront payments received or receivable | 2,524 |  | $ 3,000 |
Upfront and milestones payments included in contract liabilities | 1,084 |  |  | 1,239
Revenue recognized from upfront and milestones payments | 155 | 155 |  |
Boehringer Ingelheim |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |
Upfront payments received or receivable | 30,000 |  |  |
Revenue recognized from upfront and milestones payments |  | 2,051 |  |
Genmab |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |
Upfront payments received or receivable | 8,937 |  | $ 10,000 |
Upfront and milestones payments included in contract liabilities | 4,469 |  |  | 5,362
Revenue recognized from upfront and milestones payments | 894 | 894 |  |
GSK |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |
Upfront payments received or receivable | 205,000 |  |  |
Upfront and milestones payments included in contract liabilities | 114,725 |  |  | € 135,494
Revenue recognized from upfront and milestones payments | 30,769 | € 24,631 |  |
Minimum | GSK |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |
Upfront payments received or receivable | € 10,000 |  |  |

X
- Definition Amount of upfront payments of the company included in contract liabilities. + References No definition available. + Details
Name: | cvac_UpfrontPaymentsIncludedInContractLiabilities
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of upfront payments received or receivable by the company. + References No definition available. + Details
Name: | cvac_UpfrontPaymentsReceivedOrReceivable
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 116 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_b&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_CrisprMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GenmabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |